Biogen Q4 results beat; forecasts 2026 adj EPS $15.25-$16.25

Biogen

06/02/2026 12:05

Overview

Biotechnology firm's Q4 2025 revenue beat analyst expectations

Adjusted EPS for Q4 2025 beat analyst expectations

Company expects 2026 revenue to decline by mid-single digit percentage

Outlook

Biogen expects full-year 2026 revenue to decline by mid-single digits compared to 2025

Biogen projects 2026 Non-GAAP diluted EPS between $15.25 and $16.25

Company anticipates 2026 Non-GAAP effective tax rate of 17% to 18%

Result Drivers

GROWTH PRODUCTS - LEQEMBI, SKYCLARYS, and ZURZUVAE showed significant sales growth, contributing to overall revenue increase

PIPELINE PROGRESS - FDA Priority Review for LEQEMBI IQLIK and Breakthrough Therapy Designation for litifilimab highlight pipeline momentum

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$2.30 bln
$2.20 bln (27 Analysts)
Q4 Adjusted EPS
Beat
$1.99
$1.59 (26 Analysts)
Q4 EPS
-$0.33


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 20 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Biogen Inc is $187.00, about 0.9% above its February 5 closing price of $185.36

The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 10 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)